DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2303989/astrazeneca-azn-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2303989 Jul 17, 2024 - In the closing of the recent trading day, Astrazeneca (AZN) stood at $79.76, denoting a +1.49% change from the preceding trading day. 0

https://www.zacks.com/stock/news/2303768/fda-accepts-lexicon-s-lxrx-nda-for-type-i-diabetes-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2303768 Jul 17, 2024 - The FDA accepts Lexicon's (LXRX) resubmission seeking approval for sotagliflozin to treat adults with type 1 diabetes. A final decision is expected by Dec 20. 0

https://www.zacks.com/commentary/2299156/top-stock-reports-for-novo-nordisk-abbvie-astrazeneca?cid=CS-ZC-FT-research_daily-2299156 Jul 10, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), AbbVie Inc. (ABBV) and AstraZeneca PLC (AZN), as well as two micro-cap stocks, Air T, Inc. (AIRT) and United-Guardian, Inc. (UG). 0

https://www.zacks.com/stock/news/2297268/astrazeneca-s-azn-tagrisso-gets-eu-nod-for-first-line-nsclc?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2297268 Jul 05, 2024 - The European Commission approves AstraZeneca's (AZN) Tagrisso in combination with chemotherapy for first-line treatment of advanced EGFR-mutated NSCLC based on data from the phase III FLAURA2 study. 0

https://www.zacks.com/stock/news/2297256/pharma-stock-roundup-fda-nod-to-lly-s-kisunla-sny-s-dupixent-gets-eu-nod-for-copd?cid=CS-ZC-FT-analyst_blog|stock_roundup-2297256 Jul 05, 2024 - Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe. 0

https://www.zacks.com/stock/news/2296220/astrazeneca-azn-imfinzi-combo-gets-chmp-nod-for-expanded-use?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2296220 Jul 02, 2024 - The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from the phase III DUO-E study. 0

https://www.zacks.com/stock/news/2295002/why-astrazeneca-azn-is-a-top-growth-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_growth_score-2295002 Jun 28, 2024 - The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. 0

https://www.zacks.com/stock/news/2294903/pharma-stock-roundup-fda-s-crl-to-mrk-abbv-phase-iii-study-failures-for-nvo-azn?cid=CS-ZC-FT-analyst_blog|stock_roundup-2294903 Jun 28, 2024 - FDA rejects Merck (MRK) and AbbVie's (ABBV) filings for pipeline candidates. AstraZeneca (AZN) and Novo Nordisk (NVO) announce study failures. 0

https://www.zacks.com/stock/news/2294389/merck-s-mrk-lung-cancer-candidate-faces-fda-rejection?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2294389 Jun 27, 2024 - The FDA's CRL to Merck (MRK) and its partner Daiichi Sankyo for the patritumab deruxtecan BLA is based on observations made on inspection of a third-party manufacturing facility. 0

https://www.zacks.com/stock/news/2293892/fda-accepts-ionis-ions-nda-for-rare-disease-drug-olezarsen?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2293892 Jun 26, 2024 - The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024. 0